FDA Approves Nipocalimab for Generalized Myasthenia Gravis Dr. Kamal Kant Kohli1 May 2025 7:00 AM ISTThe US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and children aged 12 and older with...
JnJ Nipocalimab gets USFDA Fast Track designation for Sjogren's disease Ruchika Sharma19 March 2025 1:30 PM ISTSpring House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for...
JnJ Nipocalimab gets USFDA Priority Review designation for generalized myasthenia gravis Ruchika Sharma12 Jan 2025 3:30 PM ISTSpring House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review designation...
USFDA grants Breakthrough Therapy Designation to Nipocalimab for treatment of adults with moderate-to-severe Sjögren's disease: JnJ Ruchika Sharma12 Nov 2024 1:00 PM ISTSpring House: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy...
JnJ seeks approval of nipocalimab to treat generalized myasthenia gravis Ruchika Sharma2 Sept 2024 4:29 PM ISTSpring House: Johnson & Johnson has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug...
Nipocalimab Delays or Prevents Fetal Anemia and Intrauterine Transfusions in High-Risk HDFN Pregnancies: NEJM Medha Baranwal29 Aug 2024 8:00 PM ISTUSA: A recent phase 2 study has revealed that nipocalimab, an investigational treatment, demonstrates significant benefits in managing early-onset...
USFDA grants Fast Track designation to JnJ nipocalimab to reduce fetal neonatal alloimmune thrombocytopenia risk in alloimmunized pregnant adults Ruchika Sharma27 March 2024 12:30 PM ISTSpring House: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) for...
USFDA grants Breakthrough Therapy Designation for JnJ Nipocalimab for individuals at high risk for severe hemolytic disease of fetus, newborn Ruchika Sharma10 Feb 2024 12:06 PM ISTSpring House: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation...
Pharma Deal of the year: Johnson & Johnson to acquire Momenta for 6.5 billion USD Ruchika Sharma21 Aug 2020 3:14 PM ISTUS: Johnson & Johnson agreed to pay $6.5 billion in cash to acquire Momenta Pharmaceuticals Inc., a maker of autoimmune-disease drugs, in the...
